Novartis Stock Today

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
Novartis is selling at 87.47 as of the 15th of July 2020; that is 1.61 percent increase since the beginning of the trading day. The stock's lowest day price was 85.93. Novartis has about a 27 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 30 days. Equity ratings for Novartis AG are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 16th of April 2020 and ending today, the 15th of July 2020. Click here to learn more.
Analyze Filter   Report: 21st of July 2020

   Performance
0 100 

   Odds of Distress
27  

Novartis Profile

The upcoming quarterly report is expected on the 21st of July 2020. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 109000 people. more on Novartis
Novartis Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Novartis AG SEC Filings
Novartis SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameNovartis AG
Older SymbolNVSEF
President CEOChris IlsleyView All
Thematic Classifications
Active investing themes Novartis currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
    Drugs
    Healthcare
showing 2 out of 3 themes  View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Novartis AG. The Novartis consensus assessment is calculated by taking the average estimates from all of the analysts covering Novartis
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Novartis AG financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 6 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares2.6 B2.3 B
Moderately Up
Increasing
Slightly volatile
Net Cash Flow from Operations12.7 B13.6 B
Notably Down
Decreasing
Very volatile
Total Assets134.4 B118.4 B
Moderately Up
Increasing
Slightly volatile
Total Liabilities64.8 B62.8 B
Sufficiently Up
Increasing
Slightly volatile
Current Assets32.5 B29.5 B
Significantly Up
Increasing
Stable
Current Liabilities29.2 B28.3 B
Sufficiently Up
Increasing
Slightly volatile
Total Debt28.7 B29.3 B
Fairly Down
Increasing
Slightly volatile
Return on Average Assets0.08210.089
Significantly Down
Decreasing
Very volatile
Gross Margin0.660.704
Notably Down
Decreasing
Slightly volatile
Asset Turnover0.370.369
Slightly Up
Decreasing
Slightly volatile
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Novartis available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Strong HoldUndervalued
Financial Strength
Novartis financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Novartis success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
  Operating Cash Flow
Novartis AG (NVS) is traded on BATS Exchange in USA. It is located in Lichtstrasse 35 and employs 109,000 people. Novartis AG was previously known as NOVARTIS AG and was traded on BATS Exchange under the symbol NVSEF. Novartis is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with total capitalization of 198.54 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novartis's market, we take the total number of its shares issued and multiply it by Novartis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Novartis AG runs under Healthcare sector within Drug Manufacturers?General industry. The entity has 2.29 B outstanding shares of which 2.56 M shares are now shorted by investors with about 0.88 days to cover shorted positions. Novartis AG has about 4.76 B in cash with 14.24 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.08.
Check Novartis Probability Of Bankruptcy

Ownership Allocation (%)

Novartis Stock Price Odds Analysis

Odds Down 87.47HorizonTargetOdds Up 87.47
65.13%30 days
 87.47 
34.42%
Based on a normal probability distribution, the odds of Novartis to move above the current price in 30 days from now is about 34.42 (This Novartis AG probability density function shows the probability of Novartis Stock to fall within a particular range of prices over 30 days) .

Novartis Income Statement Over Time

Novartis AG Income Statement is one of the three primary financial statements used for reporting Novartis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Novartis AG revenue and expense. Novartis Income Statement primarily focuses on the company's revenues and expenses during a particular period. Novartis Research and Development Expense is relatively stable at the moment as compared to the past year. Novartis reported last year Research and Development Expense of 9.4 Billion. As of 07/15/2020, Weighted Average Shares is likely to grow to about 2.6 B, while Gross Profit is likely to drop slightly above 32.6 B. View More Fundamentals

Novartis Stock Against Markets

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Novartis Upcoming and Recent Events

Novartis Company Earnings Announcements Dates

Upcoming Quarterly Report21st of July 2020
Next Earnings Report27th of October 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End3rd of February 2021
Last Quarter Report31st of March 2020
Last Earning Announcement30th of June 2019

Novartis Corporate Filings

Novartis SEC Reporting

Other Events
View

Novartis Distributions to stockholders

A dividend is the distribution of a portion of Novartis earnings, decided and managed by the Novartiss board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Novartis dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment.
3rd of March 2020
9th of April 2019
4th of March 2019

Novartis Corporate Directors

Ton Buechner Non-Executive Independent Director
Pierre Landolt Member of the Board of Directors
Elizabeth Doherty Non-Executive Independent Director
Additionally, see Stocks Correlation. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page